Rxsight Inc
RXST
查看详细走势图
10.930USD
-0.530-4.62%
收盘 12/26, 16:00（美东）报价延迟15分钟
449.02M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-4.62%
5天
-9.14%
1月
-5.12%
6月
-13.73%
今年开始到现在
-68.21%
1年
-68.06%
查看详细走势图
TradingKey Rxsight Inc股票评分
单位: USD 更新时间: 2025-12-26操作建议
Rxsight Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在医疗设备与耗材行业排名72/207位。机构持股占比非常高，近一月多位分析师给出公司评级为持有。最高目标价10.00。中期看，股价处于上升通道。近一个月，市场表现一般，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
Rxsight Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
11
位分析师
持有
评级
10.000
目标均价
-20.38%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Rxsight Inc亮点
亮点风险
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
业绩高增长
公司营业收入稳步增长，连续3年增长185.54%
估值高估
公司最新PE估值-12.47，处于3年历史高位
机构减仓
最新机构持股38.67M股，环比减少19.32%
CI 精选加拿大股票基金持仓
明星投资者CI 精选加拿大股票基金持仓，最新持仓市值3.57K
Rxsight Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Rxsight Inc简介
RxSight, Inc. is a commercial-stage medical technology company dedicated to providing customized vision to patients following cataract surgery. The Company's proprietary RxSight Light Adjustable Lens system (RxSight system) is commercially available premium cataract technology that enables doctors to customize and optimize visual acuity for patients after surgery. The RxSight system consists of its RxSight Light Adjustable Lens (LAL), the RxSight Light Delivery Device (LDD), and accessories. Its LAL is an intraocular lens (IOL) made of photosensitive material that changes shape in response to specific patterns of ultraviolet (UV) light generated by its LDD. In contrast, with the RxSight system, the surgeon implants the LAL during a standard cataract procedure, determines refractive error with patient input several weeks following surgery and then uses the LDD to modify the LAL with the precise visual correction needed to achieve the patient's desired vision outcomes.
公司代码RXST
公司Rxsight Inc
CEOKurtz (Ron M)
网址https://www.rxsight.com/
常见问题
Rxsight Inc(RXST)的当前股价是多少？
Rxsight Inc(RXST)的当前股价是 10.930。
Rxsight Inc的股票代码是什么？
Rxsight Inc的股票代码是RXST。
Rxsight Inc股票的52周最高点是多少？
Rxsight Inc股票的52周最高点是37.130。
Rxsight Inc股票的52周最低点是多少？
Rxsight Inc股票的52周最低点是6.320。
Rxsight Inc的市值是多少？
Rxsight Inc的市值是449.02M。
Rxsight Inc的净利润是多少？
Rxsight Inc的净利润为-27.45M。
现在Rxsight Inc(RXST)的股票是买入、持有还是卖出？
根据分析师评级，Rxsight Inc(RXST)的总体评级为持有，目标价格为10.000。
Rxsight Inc(RXST)股票的每股收益（EPS TTM）是多少
Rxsight Inc(RXST)股票的每股收益（EPS TTM）是-0.877。
相关品种
+1.30%
+0.29%
+0.03%
+0.11%
-0.49%
-0.05%
-0.13%
-0.75%
+0.67%
+0.59%
+1.91%
+0.59%
+0.34%
+0.09%
+0.04%
+0.64%
+0.26%
+0.05%
+0.26%
+0.67%
